1. Clinical investigational studies for validation of a next-generation sequencingin vitrodiagnostic device for cystic fibrosis testing
- Author
-
Wendy M Goldstein, Daynna J. Wolff, Jay Stoerker, Julie A. Woolworth, Erick Lin, W. Edward Highsmith, Manjula Chelliserry, Jonathan San, Kenneth J. Friedman, Kristina M. Kruglyak, Patricia Devers, Sharmili Moturi, Ross Edward Lenta, Frank S Ong, Lynda Hague, Barbara Elashoff, Brandy Klotzle, Eric Peters, and Daniel S. Grosu
- Subjects
Sanger sequencing ,Reproducibility ,Cystic Fibrosis ,business.industry ,High-Throughput Nucleotide Sequencing ,Reproducibility of Results ,Sequence Analysis, DNA ,Sequencing by synthesis ,medicine.disease ,Sensitivity and Specificity ,Cystic fibrosis ,Molecular biology ,In vitro diagnostic ,DNA sequencing ,Pathology and Forensic Medicine ,symbols.namesake ,Molecular Diagnostic Techniques ,Genetics ,medicine ,symbols ,Humans ,Molecular Medicine ,business ,Molecular Biology - Abstract
Clinical investigational studies were conducted to demonstrate the accuracy and reproducibility of the Illumina MiSeqDx CF System, a next-generation sequencing (NGS) in vitro diagnostic device for cystic fibrosis testing.Two NGS assays - a Clinical Sequencing Assay (Sequencing Assay) and a 139-Variant Assay (Variant Assay) - were evaluated in both an Accuracy Study and a Reproducibility Study, with comparison to bi-directional Sanger sequencing and PCR as reference methods. For each study, positive agreement (PA), negative agreement (NA), and overall agreement (OA) were evaluated.In the Accuracy Study, the Sequencing Assay achieved PA of 99.7% including the polyTG/polyT region and PA of 100% excluding the region. The Variant Assay achieved PA of 100%. NA and OA were99.99% for both Assays. In the Reproducibility Study, the Sequencing Assay achieved PA of 99.2%; NA and OA were both 99.7%. The Variant Assay achieved PA of 99.8%; NA and OA were both 99.9%. Sample pass rates were 99.7% in both studies for both assays.This is the first systematic evaluation of a NGS platform for broad clinical use as an in vitro diagnostic, including accuracy validation with multiple reference methods and reproducibility validation at multiple clinical sites. These NGS-based Assays had accurate and reproducible results which were comparable to or better than other methods currently in clinical use for clinical genetic testing of cystic fibrosis.
- Published
- 2014
- Full Text
- View/download PDF